Skip to main content
Glama

Smithsonian

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.6/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond the readOnly/idempotent annotations, the description discloses graceful degradation when GLEIF/OpenFIGI is unavailable, non-resolution behavior via figi_candidates and unresolved, the internal cascading of lookup endpoints, and the ISIN-to-LEI ownership path. These are material behaviors an agent needs to interpret results correctly.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness3/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The content is front-loaded with examples and purpose, but the company type block is a dense run-on parenthetical that mixes matching rules, failure modes, and identifier sources into one massive sentence. It is informative but not concise; it could be broken into bullets without losing meaning.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description carries the full burden of explaining return behavior, and it does so thoroughly: canonical identifiers, figi_candidates when ambiguous, unresolved fields, ownership enrichment, and fallback behavior are all covered. Nothing essential for correctly invoking or interpreting the tool is missing.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Even though the input schema already documents both parameters well, the description adds decision-relevant semantics: pass the ENTITY NAME ONLY, trailing security-class words fail FIGI matching, a bond issuer must be supplied exactly as printed, and the ISIN example enriches the value meaning. This goes beyond the schema's basic ticker/CIK/name guidance.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description defines a precise job—'resolve a user-spoken NAME to the canonical/official identifiers other tools require as input'—with a specific verb, resource, and two explicit entity types. It is clearly differentiated from siblings like entity_profile and compare_entities by naming its role as the identity-lookup step ('Use FIRST whenever you have a name but need an ID').

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It gives an explicit trigger condition ('Use FIRST whenever you have a name but need an ID') and enumerates the supported lookup inputs for company and drug. It does not name the alternative tools or explicitly say when not to use it, but the context is unambiguous enough for an agent to select it.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Smithsonian toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.9/5.0
Disambiguation3/5

Many tools serve overlapping purposes, such as the three ask_pipeworx variants (stable, beta, grounded) and the six Polymarket-specific tools. While detailed descriptions help distinguish them, an agent could still confuse bet_research with polymarket_edges or the ask_pipeworx versions.

Naming Consistency2/5

Naming is highly inconsistent: verb_noun (ask_pipeworx, compare_entities), noun_noun (bet_research, entity_profile), single verbs (forget, recall, search), and adjective_noun (recent_alerts, deep_research). No clear pattern emerges across the set.

Tool Count3/5

33 tools is on the high side for a server named 'Smithsonian' that actually covers a broad range of data sources (SEC, FDA, Polymarket, npm, etc.). The number feels borderline heavy but is still manageable if the server's true purpose is general research.

Completeness4/5

The tool set covers multiple domains (company financials, drugs, economics, prediction markets, npm, museum data) with reasonable depth. Minor gaps exist, such as lack of PyPI scanning or missing update/delete operations for some memory features, but core workflows are well-supported.

Resources